

**AZURIN AND ITS DERIVATIVES FOR
PROSTATE CANCER DETECTION AND
THERAPY**

RITU BHARDWAJ



**DEPARTMENT OF BIOCHEMICAL ENGINEERING AND
BIOTECHNOLOGY**

INDIAN INSTITUTE OF TECHNOLOGY DELHI

MAY 2024

© Indian Institute of Technology Delhi (IITD), New Delhi, 2024

Azurin and its Derivatives for Prostate Cancer Detection and Therapy

by


RITU BHARDWAJ

Department of Biochemical Engineering and Biotechnology

Submitted

in fulfilment of the requirements of the degree of Doctor of Philosophy

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

May 2024

To my parents,

*Whose endless love and support have sustained
me.*

*My thanks and love go to my younger brother,
Ashu for being my pillar of strength.*

CERTIFICATE

This is to certify that the thesis entitled “**Azurin and its Derivatives for Prostate Cancer Detection and Therapy**” submitted by **Ms. Ritu Bhardwaj** to the Indian Institute of Technology Delhi for the award of the degree of **Doctor of Philosophy** in Biochemical Engineering and Biotechnology, is a record of the authentic research work carried out by her under my supervision and guidance. She has fulfilled all the requirements for submission of this thesis, which to the best of my knowledge has reached the required standards. The results presented in this thesis have not been submitted in part or full to any other university or institute for the award of any other degree or diploma.

Professor Prashant Mishra

Department of Biochemical Engineering and Biotechnology
Indian Institute of Technology Delhi
Hauz Khas – 110016,
New Delhi, India

ACKNOWLEDGEMENTS

My profound gratitude goes out to my supervisor **Prof. Prashant Mishra**, for his constant support and assistance during my research endeavour. His broad knowledge, skills and passion have greatly influenced my studies, forced me to exercise critical thoughts and motivated me to strive for perfection. His wise words, helpful criticism, and constructive input were really helpful in guiding the course of my research and honing my concepts. I was fortunate to have a supervisor who always allowed me to design the project I wanted to work on. This freedom in our work environment has allowed me to grow as an independent researcher which is crucial for my future endeavours in this field. He has consistently maintained a calm and upbeat atmosphere in the lab. I sincerely appreciate all of his help and mentoring during my academic career. His confidence in me has been crucial to my growth on both a personal and professional level.

I would like to express my sincere gratitude to the members of my SRC- **Prof. Saroj Mishra, Prof. Bishwajit Kundu, Prof. Preeti Srivastava and Prof. Shilpi Sharma**, for their invaluable contributions and insightful inputs into my research. I am also grateful to **Dr. Sujata Sinha** for her warmth and care during this PhD journey. She is my go-to person whenever I face challenges. Her wisdom, support and encouraging words have always stirred enthusiasm in me, ensuring that I remained on track.

I would like to express my heartfelt gratitude to my present and past lab members, for creating a positive and enriching lab environment. A special thanks and my heartfelt gratitude go to **Dr. Senthil** for teaching and helping me in learning the basics of animal cell culture lab techniques. I've gained valuable insights into proper experimental techniques and effective laboratory management through his guidance. I thank my colleagues and juniors- **Debashree, Kritika, Sumit, Surbhi, Shubham, Preetha, Riya, Priyanshu, Shrutika, Kapil, Ashutosh and Archi** for their support and

contributions in miscellaneous ways. I thank my seniors- **Dr. Neeti, Dr. Swati Jaiswal, Dr. Sanjay Singh and Dr. Tushar Dash** for being so hospitable and patient with me during my initial days in the lab.

Friendship is the comfort of knowing that even on your darkest days, you have someone by your side who will never let you face them alone. I would also like to express my gratitude to my friend, **Dr. Ekta Sachdeva** who went all her way to help me when resources were scarce at IITD. Her gesture and intentions are deeply appreciated. My PhD journey wouldn't have been the same without my friend and batchmate **Dr. Pravina**. I thank her for being a supportive friend when I needed it the most. The coffee and tea sessions with her, where we would vent about our PhD stress, discuss life's purpose beyond this degree making it more meaningful, driven and not affected by any setbacks, were incredibly rejuvenating and much needed. Also, I would like to thank my friend and batchmate **Dr Anjali Dixit** from KSBS, IITD who helped me in other miscellaneous aspects in my Ph. D project.

Finally, I thank my wonderful family from the bottom of my heart. My appreciation goes out to my parents, **Mrs. Munesh Sharma** and **Mr. Brehm Dutt Sharma**, for their unwavering love, sacrifice, and support during my doctoral journey. I am aware that I could not have succeeded in this without their assistance. No matter what, they have always been there for me. I would especially like to thank my mother, who has always inspired me to pursue my desires and dreams. She helped me to feel better and gave me the inspiration to keep trying even on the difficult days when I was depressed and anxious. The steadfast faith and capacity of my parents to recognize my potential despite my setbacks has been important. They have been the foundation of my strength, cheering on every little victory. Everything I have accomplished is a result of their love and leadership. I want to thank my siblings, **Renu Bhardwaj** and **Ashu Bhardwaj**. They've always brought me comfort and affection with their compassionate attitude. Even if they didn't understand the root cause, they could always make me feel better when I was down. I'm thankful to have them by my side since I know I can always

rely on them to support me, no matter what. I would also like to extend my gratitude to my brother-in-law, **Mr. Rajeev Sharma** for always expressing his pride in me so loudly and consistently. This has given me the much-needed boost in confidence. Lastly, but perhaps most importantly, I am grateful to have the two tiny creations in my life, my darling niece **Shreeya** and my little pet dog **Ray**. They both have been a constant source of joy in my life. They have brought such immense love and affection for me since the day they came into my life. Spending time with them was the ideal way for me to decompress during this journey.

I am thankful to IIT Delhi for providing excellent infrastructure and facilities that have greatly supported my research journey. The availability of state-of-the-art instruments and equipment through the Central Research Facility (CRF) has been instrumental in conducting my experiments effectively. I thank MHRD, Govt of India, for granting me the fellowship to carry out my research work at IIT Delhi and IIT Delhi for providing the travel grant RSTA to attend a conference in Australia during my tenure.

Ritu Bhardwaj

ABSTRACT

Despite diagnostic advancements in prostate cancer, early detection of aggressive forms remains challenging. Prostate specific antigen (PSA) screening, followed by biopsy, is the standard diagnostic method. However, this approach is hampered by over-detection and inability to differentiate between dormant and aggressive tumors by PSA, leading to unnecessary invasive procedures and overtreatment. Prostate specific membrane antigen (PSMA), a tissue-based biomarker linked to prostate cancer aggressiveness has shown promise, but heterogeneity in expression necessitates exploration of new biomarkers. Treatments like surgery, radiotherapy, hormonal therapy, chemotherapy and immunotherapy have lessened the burden of metastatic prostate cancer. Nonetheless, undesirable side effects like recurrence and development of insensitive and resistant tumors makes it imperative to search for alternative treatment approaches.

Protein-based nanomedicines have emerged as promising alternative in cancer detection and therapy by utilizing diverse functional properties of various proteins to overcome the limitations of conventional small molecules drugs. In contrast to conventional chemotherapy, protein-based nanomedicines offer precise targeting, reduced off-target effects and enhanced therapeutic efficacy. In the present work, novel composite protein engineered nanomedicines were designed while conjugating different class of proteins via genetic engineering for prostate cancer management.

Erythropoietin-producing hepatocellular (Eph) receptors a subfamily of receptor tyrosine kinases, play a pivotal role in cancer development and progression. Thus, Ephs, have emerged as prominent cancer biomarkers due to their aberrant expression with cancer progression. Azurin, a bacterial protein isolated from *Pseudomonas aeruginosa*, has demonstrated its potential in inhibiting tumor progression by disrupting Eph–ephrin signaling via its C-terminal domain as one of the mechanisms. In prostate cancer, overexpression of EphA6 receptors has been associated with prostate cancer metastasis. Thus, for the first-time cell surface receptor, EphA6 has been explored as a theranostic biomarker for detecting and simultaneously killing of metastatic prostate cancer in *in vitro* studies. The *in silico* binding studies, demonstrated that the fusion protein, his₆EGFP-azu (80–128) exhibited higher binding affinity for the EphA6 receptor compared to traditional ephrin A ligands via azu (80–128) peptide. Inspired by the *in*

silico binding studies, a novel recombinant protein his₆EGFP-azu (80-128) was designed, cloned, expressed, and purified. The his₆EGFP-azu (80–128) fusion protein, spontaneously self-assembled as nanoparticles, effectively targeted EphA6 receptors on prostate cancer cells (LNCaP) and demonstrated remarkable imaging potential, antiproliferative, apoptotic, antimigratory, and anti-invasive effects, while sparing EphA6-negative human normal lung cells (WI-38).

Further, to enhance the therapeutic efficacy of azurin via its nanodelivery as cross-linked azurin-ELP micelles, a fusion protein composed of azurin and a thermally responsive structural cationic elastin-like protein (ELP), was designed, cloned, expressed, and purified. A simple method of inverse transition cycle (ITC) was employed to purify the fusion protein azurin-ELP diblock copolymer (d-bc). Further, its self-assembly properties were investigated. Interestingly, the engineered azurin-ELP d-bc in response to increasing temperature shows a dual step phase separation into bio-functional nanostructures. Around physiological temperature azurin-ELP d-bc formed stable coacervates which was dependent on the concentration and time of incubation. These coacervates were formed below the lower critical solubility temperature (LCST) of the ELP block at physiological temperature. Above LCST micelles of size ranging from 25-30 nm are formed. The cytotoxicity of azurin-ELP d-bc depends on the size of coacervates formed and their cellular uptake at physiological temperature. Further, MTT assay of azurin-ELP d-bc in the cross-linked micelles prepared *ex situ* showed > six times higher killing of LNCaP cells than the unimeric form of azurin-ELP at 5 μM concentration. The flow cytometric results of these micelles at 20 μM concentration showed, ~97 % LNCaP cells in apoptotic phase. Thus, azurin-ELP cross-linked micelles enhanced potential for anticancer therapy due to their higher avidity.

Thus, in retrospect protein-engineered nanomedicines based on the recombinant proteins, azurin-ELP and his₆EGFP-azu (80–128) were designed by fusing, an anticancer bacterial protein, azurin with a thermoresponsive structural protein, ELP and azurin's peptide azu (80-128) with fluorescent protein EGFP, respectively. The unique functions of both the components in the fusion systems aided in the nanoscale self-assembly of the recombinant proteins to achieve enhanced therapeutic effect along with real time imaging of the prostate cancer cells. The work collectively represents innovative approaches for targeting prostate cancer aiming to overcome the limitations associated with conventional approach. These findings contribute

valuable insights to the evolving field of protein-based nanotherapeutics and nanotheranostics with significant potential for precision cancer therapy.

सार

प्रोस्टेट कैंसर में नैदानिक प्रगति के बावजूद, आक्रामक रूपों का शीघ्र पता लगाना चुनौतीपूर्ण बना हुआ है। प्रोस्टेट विशिष्ट एंटीजन (पीएसए) स्क्रीनिंग, उसके बाद बायोप्सी, मानक निदान पद्धति है। हालाँकि, पीएसए द्वारा अति-पहचान और निष्क्रिय और आक्रामक ट्यूमर के बीच अंतर करने में असमर्थता के कारण यह दृष्टिकोण बाधित होता है, जिससे अनावश्यक आक्रामक प्रक्रियाएं और अत्यधिक उपचार होता है। प्रोस्टेट विशिष्ट झिल्ली एंटीजन (पीएसएमए), प्रोस्टेट कैंसर की आक्रामकता से जुड़ा एक ऊतक आधारित बायोमार्कर ने वादा दिखाया है, लेकिन अभिव्यक्ति में विविधता के कारण नए बायोमार्कर की खोज की आवश्यकता होती है। सर्जरी, रेडियोथेरेपी, हार्मोनल थेरेपी, कीमोथेरेपी और इम्यूनोथेरेपी जैसे उपचारों ने मेटास्टैटिक प्रोस्टेट कैंसर के बोझ को कम कर दिया है। बहरहाल, असंवेदनशील और प्रतिरोधी ट्यूमर की पुनरावृत्ति और विकास जैसे अवांछनीय दुष्प्रभाव वैकल्पिक उपचार दृष्टिकोण की खोज करना अनिवार्य बनाते हैं।

पारंपरिक छोटे अणुओं वाली दवाओं की सीमाओं को दूर करने के लिए विभिन्न प्रोटीनों के विविध कार्यात्मक गुणों का उपयोग करके प्रोटीन-आधारित नैनोमेडिसिन कैंसर का पता लगाने और उपचार में एक आशाजनक विकल्प के रूप में उभरी है। पारंपरिक कीमोथेरेपी के विपरीत, प्रोटीन-आधारित नैनोमेडिसिन सटीक लक्ष्यीकरण, कम-लक्ष्य प्रभाव और बढ़ी हुई चिकित्सीय प्रभावकारिता प्रदान करती है। वर्तमान कार्य में, प्रोस्टेट कैंसर प्रबंधन के लिए आनुवंशिक इंजीनियरिंग के माध्यम से प्रोटीन के विभिन्न वर्ग को संयुग्मित करते हुए नवीन मिश्रित प्रोटीन इंजीनियर नैनोमेडिसिन डिजाइन किए गए थे। एरिथ्रोपोइटिन-उत्पादक हेपैटोसेलुलर (ईएफ) रिसेप्टर्स, रिसेप्टर टायरोसिन किनेसेस का एक उपपरिवार, कैंसर के विकास और प्रगति में महत्वपूर्ण भूमिका निभाते हैं। इस प्रकार, कैंसर की प्रगति के साथ उनकी असामान्य अभिव्यक्ति के कारण इप्रस प्रमुख कैंसर बायोमार्कर के रूप में उभरे हैं। स्यूडोमोनास एरुगिनोसा से अलग किया गया एक जीवाणु प्रोटीन, अजुरिन, ने एक तंत्र के रूप में अपने सी-टर्मिनल डोमेन के माध्यम से एफ़-एफ़िन सिग्नलिंग को बाधित करके ट्यूमर की प्रगति को रोकने में अपनी क्षमता का प्रदर्शन किया है। प्रोस्टेट कैंसर में, EphA6 रिसेप्टर्स की अधिक अभिव्यक्ति प्रोस्टेट कैंसर मेटास्टेसिस से जुड़ी हुई है। इस प्रकार, पहली बार कोशिका सतह रिसेप्टर, EphA6 को इन विट्रो अध्ययनों में मेटास्टैटिक प्रोस्टेट कैंसर का पता लगाने और साथ ही मारने के लिए एक चिकित्सीय बायोमार्कर के रूप में खोजा गया है। सिलिको बाइंडिंग अध्ययनों से पता चला है कि संलयन प्रोटीन, his₆EGFP-azu (80-128) ने azu (80-128) पेप्टाइड के माध्यम से पारंपरिक एफ़िना लिगैंड की तुलना में EphA6 रिसेप्टर के

लिए उच्च बाध्यकारी संबंध प्रदर्शित किया है। सिलिको बाइंडिंग अध्ययनों से प्रेरित होकर, एक नवीन पुनः संयोजक प्रोटीन his₆EGFP-azu (80-128) को डिजाइन, क्लोन, व्यक्त और शुद्ध किया गया था। his₆EGFP-azu (80-128) संलयन प्रोटीन, नैनोकणों के रूप में स्वतः एकत्रित होकर, प्रोस्टेट कैंसर कोशिकाओं (LNCaP) पर EphA6 रिसेप्टर्स को प्रभावी ढंग से लक्षित करता है और EphA6-नकारात्मक मानव सामान्य फेफड़ों की कोशिकाओं (WI-38) को बख्शाते हुए उल्लेखनीय इमेजिंग क्षमता, एंटीप्रोलिफेरेटिव, एपोप्टोटिक, एंटीमाइग्रेटरी और एंटी-इनवेसिव प्रभावों का प्रदर्शन करता है।

इसके अलावा, क्रॉस-लिंकड एजुरिन-ईएलपी मिसेल्स के रूप में नैनोडिलीवरी के माध्यम से अजुरिन की चिकित्सीय प्रभावकारिता को बढ़ाने के लिए, अजुरिन से बना एक संलयन प्रोटीन और एक थर्मल प्रतिक्रियाशील संरचनात्मक धनायनित इलास्टिन-जैसे प्रोटीन (ईएलपी) को डिजाइन, क्लोन, व्यक्त और शुद्ध किया गया था। संलयन प्रोटीन अजुरिन-ईएलपी डाइब्लॉक कॉपोलीमर (डी-बीसी) को शुद्ध करने के लिए व्युत्क्रम संक्रमण चक्र (आईटीसी) की एक सरल विधि को नियोजित किया गया था। इसके अलावा, इसकी सेल्फ-असेंबली संपत्तियों की जांच की गई। दिलचस्प बात यह है कि बढ़ते तापमान के जवाब में इंजीनियर्ड अजुरिन-ईएलपी डी-बीसी जैव-कार्यात्मक नैनोस्ट्रक्चर में दोहरे चरण चरण पृथक्करण को दर्शाता है। शारीरिक तापमान के आसपास अजुरिन-ईएलपी डी-बीसी ने स्थिर कोएसर्वेट्स का निर्माण किया जो ऊष्मायन की एकाग्रता और समय पर निर्भर था। ये कोएसर्वेट शारीरिक तापमान पर ईएलपी ब्लॉक के निचले महत्वपूर्ण घुलनशीलता तापमान (एलसीएसटी) से नीचे बने थे। एलसीएसटी के ऊपर 25-30 एनएम आकार के मिसेल बनते हैं। अजुरिन-ईएलपी डी-बीसी की साइटोटॉक्सिसिटी गठित कोएसर्वेट्स के आकार और शारीरिक तापमान पर उनके सेलुलर अवशोषण पर निर्भर करती है। इसके अलावा, क्रॉस-लिंकड मिसेलस तैयार पूर्व सीटू में अजुरिन-ईएलपी डी-बीसी के एमटीटी परख से पता चला कि 5 μM सांद्रता पर अजुरिन-ईएलपी के यूनिमेरिक रूप की तुलना में एलएनसीएपी कोशिकाओं की छह गुना अधिक हत्या हुई है। 20 μM सांद्रता पर इन मिसेलों के प्रवाह साइटोमेट्रिक परिणामों से पता चला, एपोप्टोटिक चरण में ~97 % LNCaP कोशिकाएं। इस प्रकार, अजुरिन-ईएलपी क्रॉस-लिंकड मिसेलस ने अपनी उच्च अम्लता के कारण कैंसर रोधी चिकित्सा की क्षमता बढ़ा दी।

इस प्रकार, पुनः संयोजक प्रोटीन पर आधारित पुनः संयोजक प्रोटीन इंजीनियर नैनोमेडिसिन में, एजुरिन-ईएलपी और उसके (80-128) को फ़्यूज़िंग द्वारा डिज़ाइन किया गया था, एक एंटीकैंसर बैक्टीरियल प्रोटीन, थर्मोरेस्पॉन्सिव संरचनात्मक प्रोटीन के साथ एजुरिन, ईएलपी और एजुरिन के पेप्टाइड azu (80 - 128) क्रमशः फ्लोरोसेंट प्रोटीन ईजीएफपी के साथ। संलयन प्रणालियों में दोनों घटकों के अनूठे कार्यों ने

प्रोस्टेट कैंसर कोशिकाओं की वास्तविक समय इमेजिंग के साथ-साथ उन्नत चिकित्सीय प्रभाव प्राप्त करने के लिए पुनः संयोजक प्रोटीन के नैनोस्केल स्व-संयोजन में सहायता की। यह कार्य पारंपरिक दृष्टिकोण से जुड़ी सीमाओं को दूर करने के उद्देश्य से प्रोस्टेट कैंसर को लक्षित करने के लिए सामूहिक रूप से नवीन दृष्टिकोण का प्रतिनिधित्व करता है। ये निष्कर्ष सटीक कैंसर थेरेपी के लिए महत्वपूर्ण क्षमता वाले प्रोटीन-आधारित नैनोथेराप्यूटिक्स और नैनोथेरानोस्टिक्स के विकसित क्षेत्र में मूल्यवान अंतर्दृष्टि प्रदान करते हैं।

TABLE OF CONTENTS

Certificate.....	i
Acknowledgements.....	ii
Abstract.....	v
संर.....	viii
Table of Contents.....	xi
List of Figures.....	xv
List of Tables.....	xvii
List of Symbols... ..	xviii
List of Abbreviations.....	xix
Chapter 1.....	1
Introduction	
Chapter 2.....	5
Literature Review	
2.1. Prostate Cancer.....	6
2.1.1. Background.....	6
2.1.2. Diagnosis.....	7
2.1.3. Treatment.....	10
2.2. Protein-Ligand Interaction-based Diagnostic, Therapeutic and Theranostics for Prostate Cancer Management	11
2.3. Role of Proteins as Therapeutic and Diagnostic Agents in Cancer.....	13
2.4. Azurin Protein as an Anticancer Agent.....	17
2.5. Challenges Associated with the Delivery of Protein Therapeutics.....	21
2.6. Protein-based Nanomedicines for Cancer Therapy and Diagnosis.....	21
2.7. Fusion of Protein Therapeutics with Self-Assembling Biopolymers.....	23
2.8. Role of Elastin--Like Polypeptides in Drug Delivery and Diagnostics	25

Chapter 3.....	29
<i>In Silico</i> Analysis of Binding Affinities of EphrinA Ligands and the Fusion Protein his₆EGFP-azu (80-128) with the Ligand Binding Domain of EphA6 (LBDEPHA6)	
3.1. Introduction.....	30
3.2. Materials and Methods.....	34
3.2.1. Softwares/servers.....	34
3.2.2. Docking Studies.....	34
3.3. Results and Discussion.....	36
3.4. Conclusion.....	45
Chapter 4.....	47
Engineering of Recombinant EGFP--Azurin Theranostic Nanosystem for Targeted Therapy of Prostate Cancer	
4.1. Introduction.....	48
4.2. Materials and Methods.....	49
4.2.1. Molecular Cloning.....	49
4.2.2. Expression and Purification of his ₆ EGFP—azu (80-128) Recombinant Protein and his ₆ EGFP Control Protein.....	50
4.2.3. Characterization of his ₆ EGFP—azu (80-128) Recombinant Protein.....	50
4.2.4. Stability of his ₆ EGFP—azu (80-128) Recombinant Protein.....	51
4.2.5. Cell Culture and Media.....	51
4.2.6. Real-Time Reverse Transcription Polymerase Chain Reaction (RT-qPCR).....	52
4.2.7. MTT Assay.....	52
4.2.8. Clonogenic Assay.....	52
4.2.9. Microscopy.....	52
4.2.10. <i>In Vitro</i> Boyden Chamber Assay	53
4.2.11. Flow Cytometry	53
4.2.11.1 Cell Binding.....	53
4.2.11.2 Live/Dead assay.....	53
4.2.11.3 Apoptosis and Cell Cycle via DNA Fragmentation Analysis.....	53
4.3. Results and Discussion.....	54
4.3.1. Cloning, Expression and Purification of the Recombinant Fusion Protein his ₆ EGFP—azu (80-128).....	54

4.3.2. Characterization of the Recombinant Fusion Protein his ₆ EGFP–azu (80-128)....	55
4.3.3. Quantification of the Relative Expression of EphA6 gene in Prostate Cancer Cells LNCaP and Human Normal Cells WI-38.....	59
4.3.4. Cell Binding and Cell Imaging Studies of Recombinant his ₆ EGFP–azu (80-128) Nanoparticles.....	60
4.3.5. Cytotoxicity Studies	63
4.3.6. Anti-Migratory and Cell-Invasion Studies of his ₆ EGFP–azu (80-128) Nanoparticles.....	66
4.4. Conclusion.....	67
Chapter 5.....	68
Multiresponsive, Temperature Triggered Nanoscale Self-Assembly of Azurin-Elastin - like Polypeptide Fusion Protein for Enhanced Prostate Cancer Therapy	
5.1. Introduction.....	69
5.2. Materials and Methods.....	71
5.2.1. Cloning, Expression, and Purification of Recombinant proteins.....	71
5.2.2. Fluorescence Spectroscopy.....	73
5.2.3. Circular Dichroism.....	73
5.2.4. Phase Transitions.....	73
5.2.5. Dynamic Light Scattering (DLS).....	74
5.2.6. Morphological Studies and Characterization of Self-Assembled Nanostructures.....	74
5.2.7. Cell Culture and Media.....	75
5.2.8. Fluorophore Conjugation.....	75
5.2.9. Cellular Uptake of Azurin-ELP d-bc Coacervates.....	75
5.2.10. MTT Assay.....	75
5.2.11. Micelles Preparation.....	76
5.2.12. Flow Cytometric Analysis of Apoptosis.....	76
5.3. Results and Discussion.....	76
5.3.1. Cloning, Expression, and Purification of Recombinant Proteins.....	76
5.3.2. Structural Characterization of the Azurin-ELP d-bc.....	77
5.3.3. Temperature Triggered Self-Assembly of Azurin-ELP d-bc.....	78

5.3.4. <i>In Vitro</i> Cytotoxicity Study and Evaluation of Cellular Uptake of Azurin-ELP d-bc Self-Assembled as Coacervates.....	86
5.3.5. Enhancement of Cytotoxicity of the Micellar Nanostructures of Azurin-ELP d-bc.....	90
5.3.6. Impact of Azurin-ELP Micelles on the Cellular Uptake of Azurin.....	95
5.4. Conclusion.....	96
Chapter 6.	98
Summary, Conclusion and Future Prospects	
References.....	103
Appendix I.....	120
Appendix II.....	122
Appendix III.....	123
Appendix IV.....	126
Appendix V.....	133
Appendix VI.....	137
Author’s Biography.....	142

LIST OF FIGURES

Figure 2.1. The most common cancers in 2020 as estimated by GLOBOCAN.

Figure 2.2. Stages in prostate cancer detection.

Figure 2.3. Classification of protein-based nanomedicine for cancer treatment.

Figure 2.4. Schematic representation of the advancement in of protein-based therapies for cancer treatment.

Figure 2.5. Anticancer agents from microbial sources.

Figure 2.6. Anticancer peptides obtained from azurin and their mechanism of action.

Figure 2.7. Schematic representation of common structures of self-assembled protein-polymer conjugates.

Figure 3.1. Schematic illustration for possible mechanisms of the recombinant fusion protein his₆EGFP-azu (80-128).

Figure 3.2. Schematic work-flow for *in silico* studies.

Figure 3.3. Docked complexes retrieved from HADDOCK 2.4 docking Web server and models obtained from superimposing the complexes.

Figure 3.4. Dim-plot graphs of protein-protein docking showing the molecular interactions between complexes.

Figure 4.1. Expression and purification of recombinant fusion protein his₆EGFP-azu (80-128).

Figure 4.2. Characterization of the purified recombinant fusion protein his₆EGFP-azu (80-128) and the control protein his₆EGFP.

Figure 4.3. Stability of the nanosystem his₆EGFP-azu in PBS and FBS.

Figure 4.4. The mRNA expression of EphA6 detected and quantitated by qRT-PCR in prostate cancer cells,

Figure 4.5. Real time cell binding and cell imaging analysis of his₆EGFP-azu (80-128) nanoparticles.

Figure 4.6. Quantitative evaluation of cytotoxicity of his₆EGFP-azu (80-128).

Figure 4.7. his₆EGFP-azu (80-128) completely inhibited the clonogenic capacity of LNCaP cells.

Figure 4.8. Morphological changes as observed by the phase contrast microscopy (20x) and flow cytometry-based DNA fragmentation/apoptosis evaluation of LNCaP cells.

Figure 4.9. Representative transwell migration and invasion assay images from LNCaP cancer cells.

Figure 5.1. Cloning, expression, and purification of recombinant protein azurin-ELP d-bc.

Figure 5.2. Structural characterization of azurin-ELP d-bc.

Figure 5.3. Thermal characterizations of azurin-ELP d-bc.

Figure 5.4. Thermally induced conformational characterizations of azurin-ELP d-bc.

Figure 5.5. *In vitro* cytotoxicity study and evaluation of cellular uptake of Azurin-ELP d-bc self-assembled as coacervates.

Figure 5.6. Structural characterization of cross-linked azurin-ELP micelles.

Figure 5.7. Cytotoxicity of the micellar nanostructures of azurin-ELP d-bc.

Figure 5.8. Comparative cytotoxicity of cancer cells treated with azurin, ELP, azurin-ELP d-bc (coacervates) and cross-linked azurin-ELP micelles.

Figure 5.9. Comparative flow cytometric analysis of cellular uptake and apoptosis level in LNCaP cancer cells treated with FITC-azurin-ELP d-bc, unimers and micelles.

LIST OF TABLES

Table 2.1. Some examples of protein-ligand interaction-based diagnostic, therapeutic and theranostic agents in prostate cancer.

Table 2.2. Anticancer effect of azurin and its peptide on different cancer cells.

Table 2.3. List of ELP-based micelles used for the delivery of therapeutic proteins and peptides.

Table 3.1. Active residues of the proteins involved in the docking.

Table 3.2. The statistical analysis of HADDOCK complexes.

Table 3.3. Summary and comparison of the *in silico* results.

Table 3.4. Comparison of the binding affinities of the present work with the existing literature on binding affinities of Eph-ephrin.

Table 4.1. The primers used for the construction of pET28a-EGFP and pET28a-EGFP-azu (80-128).

Table 5.1. The primers used for the construction of pET29a-azurin and pET29a-ELP and pET29a-ELP-azurin.

LIST OF SYMBOLS

α	alpha
β	beta
$^{\circ}\text{C}$	degree celsius
g	grams
h	hour
L	liter
μ	micro
M	molar
%	percentage
s	second
U	units
v/v	volume/volume
λ	wavelength

LIST OF ABBREVIATIONS

APS	ammonium persulfate
bp	base pairs
DNA	deoxyribonucleic acid
CD	circular dichroism
cm	centimeter
CMT	critical micellar temperature
d-bc	diblock copolymer
DSC	differential scanning calorimetry
DIC	differential interference contrast
EGFP	enhanced green fluorescent protein
ELP	elastin-like protein
Eph	erythropoietin-producing hepatocellular
FITC	fluorescein isothiocyanate
IPTG	isopropyl- β -D-thiogalactopyranoside
ITC	inverse transition cycling
kDa	kilodaltons
LB	luria bertani
LCST	lower critical solubility temperature
LNCaP	lymph node carcinoma of the prostate
μ M	micromolar
μ L	microlitre
mm	millimeter
mg	milligram
mL	millilitre

mins	minutes
nm	nanometer
MTT	3-4,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide
Ni-NTA	nickel-nitrilotriacetic acid
PAGE	polyacrylamide gel electrophoresis
PBS	phosphate buffered saline
PCR	polymerase chain reaction
RNA	ribonucleic acid
SDS	sodium dodecyl sulphate
RPM	rotation per minute
TB	terrific broth
TEM	transmission electron microscopy
TEMED	N,N,N',N'-tetramethylethylene diamine
UV	ultraviolet
w/v	weight/volume
w/w	weight/weight